Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)

Next Previous
Trial Profile

ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Blinatumomab (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Doxorubicin (Primary) ; Hydrocortisone sodium succinate (Primary) ; Imatinib (Primary) ; Inotuzumab ozogamicin (Primary) ; Mercaptopurine (Primary) ; Methotrexate (Primary) ; Methylprednisolone sodium succinate (Primary) ; Prednisolone sodium succinate (Primary) ; Tioguanine (Primary) ; Vincristine (Primary)
  • Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Acronyms ALLTogether; ALLTogether1

Most Recent Events

  • 18 Sep 2024 This trial is ongoing in Belgium according to European Clinical Trials Database record.
  • 02 May 2022 Study design of Thiopurine Enhanced ALL Maintenance (TEAM), a sub-protocol to the ALLTogether1 trial published in the BMC Cancer
  • 22 Jun 2020 Planned initiation date changed from 15 Jun 2020 to 22 Jun 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top